Abstract
Objective To evaluate the risk of endometrial cancer in women who carry a mutation in the BRCA1 or the BRCA2 gene. Methods We followed 4456 women with a BRCA1 or a BRCA2 mutation for incident cases of endometrial cancer. The incidence of endometrial cancer was estimated per 100,000 women per year. The hazard ratios for endometrial cancer were estimated by calculating standardized incidence ratios (SIRs) according to age group and country of residence. We estimated the impact of tamoxifen and hormone replacement therapy on the incidence of endometrial cancer in BRCA1 and BRCA2 carriers. Results After a mean follow-up of 5.7 years, we identified 17 endometrial cancers (13 cases in BRCA1 and 4 cases in BRCA2). The SIR for BRCA1 carriers was 1.91 (95% CI: 1.06-3.19, p = 0.03) and for BRCA2 carriers was 1.75 (95% CI: 0.55-4.23, p = 0.2). The SIR was 4.14 (95% CI: 1.92 to 7.87) for women who received tamoxifen and was 1.67 (95% CI: 0.81 to 3.07) for women who did not receive tamoxifen. The ten-year cumulative risk of endometrial cancer in women who were treated with tamoxifen was 2.0%. Conclusions The risk of endometrial cancer is higher in BRCA1 mutation carriers than in the general population. The excessive risk is largely attributable to a history of tamoxifen use, but the actual risk of endometrial cancer associated with tamoxifen is small. It is important to discuss hysterectomy at the time of prophylactic bilateral salpingo-oophorectomy if tamoxifen is to be considered.
| Original language | English |
|---|---|
| Pages (from-to) | 127-131 |
| Number of pages | 5 |
| Journal | Gynecologic Oncology |
| Volume | 130 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Obstetrics and Gynecology
- Oncology
Cite this
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations : An international prospective cohort study. / Segev, Yakir; Iqbal, Javaid; Lubinski, Jan; Gronwald, Jacek; Lynch, Henry T.; Moller, Pal; Ghadirian, Parviz; Rosen, Barry; Tung, Nadine; Kim-Sing, Charmaine; Foulkes, William D.; Neuhausen, Susan L.; Senter, Leigha; Singer, Christian F.; Karlan, Beth; Ping, Sun; Narod, Steven A.
In: Gynecologic Oncology, Vol. 130, No. 1, 07.2013, p. 127-131.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations
T2 - An international prospective cohort study
AU - Segev, Yakir
AU - Iqbal, Javaid
AU - Lubinski, Jan
AU - Gronwald, Jacek
AU - Lynch, Henry T.
AU - Moller, Pal
AU - Ghadirian, Parviz
AU - Rosen, Barry
AU - Tung, Nadine
AU - Kim-Sing, Charmaine
AU - Foulkes, William D.
AU - Neuhausen, Susan L.
AU - Senter, Leigha
AU - Singer, Christian F.
AU - Karlan, Beth
AU - Ping, Sun
AU - Narod, Steven A.
PY - 2013/7
Y1 - 2013/7
N2 - Objective To evaluate the risk of endometrial cancer in women who carry a mutation in the BRCA1 or the BRCA2 gene. Methods We followed 4456 women with a BRCA1 or a BRCA2 mutation for incident cases of endometrial cancer. The incidence of endometrial cancer was estimated per 100,000 women per year. The hazard ratios for endometrial cancer were estimated by calculating standardized incidence ratios (SIRs) according to age group and country of residence. We estimated the impact of tamoxifen and hormone replacement therapy on the incidence of endometrial cancer in BRCA1 and BRCA2 carriers. Results After a mean follow-up of 5.7 years, we identified 17 endometrial cancers (13 cases in BRCA1 and 4 cases in BRCA2). The SIR for BRCA1 carriers was 1.91 (95% CI: 1.06-3.19, p = 0.03) and for BRCA2 carriers was 1.75 (95% CI: 0.55-4.23, p = 0.2). The SIR was 4.14 (95% CI: 1.92 to 7.87) for women who received tamoxifen and was 1.67 (95% CI: 0.81 to 3.07) for women who did not receive tamoxifen. The ten-year cumulative risk of endometrial cancer in women who were treated with tamoxifen was 2.0%. Conclusions The risk of endometrial cancer is higher in BRCA1 mutation carriers than in the general population. The excessive risk is largely attributable to a history of tamoxifen use, but the actual risk of endometrial cancer associated with tamoxifen is small. It is important to discuss hysterectomy at the time of prophylactic bilateral salpingo-oophorectomy if tamoxifen is to be considered.
AB - Objective To evaluate the risk of endometrial cancer in women who carry a mutation in the BRCA1 or the BRCA2 gene. Methods We followed 4456 women with a BRCA1 or a BRCA2 mutation for incident cases of endometrial cancer. The incidence of endometrial cancer was estimated per 100,000 women per year. The hazard ratios for endometrial cancer were estimated by calculating standardized incidence ratios (SIRs) according to age group and country of residence. We estimated the impact of tamoxifen and hormone replacement therapy on the incidence of endometrial cancer in BRCA1 and BRCA2 carriers. Results After a mean follow-up of 5.7 years, we identified 17 endometrial cancers (13 cases in BRCA1 and 4 cases in BRCA2). The SIR for BRCA1 carriers was 1.91 (95% CI: 1.06-3.19, p = 0.03) and for BRCA2 carriers was 1.75 (95% CI: 0.55-4.23, p = 0.2). The SIR was 4.14 (95% CI: 1.92 to 7.87) for women who received tamoxifen and was 1.67 (95% CI: 0.81 to 3.07) for women who did not receive tamoxifen. The ten-year cumulative risk of endometrial cancer in women who were treated with tamoxifen was 2.0%. Conclusions The risk of endometrial cancer is higher in BRCA1 mutation carriers than in the general population. The excessive risk is largely attributable to a history of tamoxifen use, but the actual risk of endometrial cancer associated with tamoxifen is small. It is important to discuss hysterectomy at the time of prophylactic bilateral salpingo-oophorectomy if tamoxifen is to be considered.
UR - http://www.scopus.com/inward/record.url?scp=84879106640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879106640&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2013.03.027
DO - 10.1016/j.ygyno.2013.03.027
M3 - Article
C2 - 23562522
AN - SCOPUS:84879106640
VL - 130
SP - 127
EP - 131
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -